Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.74 AUD | +0.77% | +0.96% | +56.15% |
05-27 | Telix Pharmaceuticals Submits New Drug Application for Prostate Cancer Imaging Agent to US FDA | MT |
05-27 | Telix Pharmaceuticals Limited Submits NDA for New Prostate Cancer Imaging Agent | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+56.15% | 3.46B | |
+48.67% | 56.69B | |
-2.76% | 41B | |
+38.99% | 38.11B | |
-11.22% | 26.89B | |
+9.25% | 25.59B | |
-23.10% | 18.59B | |
+1.88% | 12.39B | |
+26.43% | 11.99B | |
+21.74% | 11.88B |
- Stock Market
- Equities
- TLX Stock
- News Telix Pharmaceuticals Limited
- Transcript : Telix Pharmaceuticals Limited, H1 2022 Earnings Call, Aug 17, 2022